Biomea Fusion doses first patient in OPAL trial of icovamenib plus semaglutide for obesityPUBT·1 day ago, 06:03 AMBMEA+3.13%
Niche Market Moves: Major Overhauls From Energy to AI InfrastructureGlobal Report·Jul 22 at 04:17 AMWLLBW0.00%BMEA+3.13%
Unbundling the Long Tail: Narrative Arbitrage and Value Chain RealitiesGlobal Report·Jul 9 at 05:03 AMNTRB+3.45%KYCCF+1.07%
Markets Weigh Cross-Sector Fundamentals for Signals on the Next Economic PhaseGlobal Report·Jul 8 at 10:32 PMNEXA-1.05%PCRHY+0.54%
Biomea Presents Promising Phase 2 Data For Icovamenib In Diabetes; Advances Phase 1 For BMF-650nasdaq·Jun 8 at 07:10 AMBMEA+3.13%
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study | BMEA Stock NewsStockTitan·Jun 5 at 10:35 AMBMEA+3.13%
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights | BMEA Stock NewsStockTitan·May 11 at 07:55 AMBMEA+3.13%
